ProfessorTim Lambert

Tim Lambert, BSc, MBBS, PhD, FRANZCP, is Professor of Psychiatry at Concord Clinical School at The University of Sydney in Australia. He also holds an appointment as Head of Schizophrenia Treatment and Outcomes Research at the Brain & Mind Research Institute in Sydney. In addition, he fulfils clinical duties for Sydney Local Health Network as Director of the Centre of Excellence in Relapse Prevention in Psychosis (CERP), and at the Concord Centre for Cardiometabolic Health in Psychosis (ccCHiP).

Professor Lambert has a portfolio of interests in translational aspects of clinical neuropharmacology and neurosciences. These span clinical psychosis research, outcomes research, service delivery models, training, and education. His current interests focus on services research (pharmacoepidemiology, developing novel relapse prevention, treatment resistance, and cardiometabolic services for the seriously mentally ill); the clinical pharmacology of LAI antipsychotics (first and second generation) and of the second-generation antipsychotics, particularly risk-benefit aspects and the applied clinical pharmacology of antipsychotic switching; physical comorbidities of psychotic disorders, especially cardiometabolic syndromes; and incomplete recovery. Social aspects, particularly the role of acculturation on clinical phenotypes permeate all facets of these programmes. In terms of education and training, his team has been developing newmedia-based approaches to education and this work has been utilised to produce educational and training materials such as CD-ROMs, DVDs and web-based applications for mental health workers in many parts of the world. He has been a principal in the development of a number of clinical practice guidelines, algorithms, and consensus documents (Diabetes and antipsychotics; RANZCP CPG for schizophrenia; Treatment Refractory Consensus Guidelines, for example). Professor Lambert is a regularly invited lecturer, clinical trainer, and consultant throughout Asia, Australia, Europe, and North America. He is a member of a number of international and national advisory groups concerned with antipsychotic treatments and their role in community psychiatry.